Biomotion Sciences Inc. Warrant (SLXNW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Biomotion Sciences Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 218,765 | $7,700.83 | $10,872.62 | $3,171.79 | 41.19% |
Biomotion Sciences Inc. Warrant (SLXNW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biomotion Sciences Inc. Warrant ever had a stock split?
Biomotion Sciences Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Ilan Hadar CEO | NASDAQ (CM) Exchange | G1281K114 CUSIP |
| IL Country | 14 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Silexion Therapeutics LTD is a pioneering biopharmaceutical entity focused on the research and development of RNA interference (RNAi)-based therapeutics specifically engineered for the treatment of malignant solid tumors. Utilizing cutting-edge scientific insights and proprietary technologies, Silexion is at the forefront of creating innovative cancer treatments. The company's commitment to combating cancer is embodied in its specialized LODER delivery platform, which is designed to optimize the delivery of therapeutic agents directly to tumor sites. Founded in 2008, Silexion Therapeutics has established its headquarters in Jerusalem, Israel, positioning itself as a notable player in the global oncology research landscape.
Products and Services
-
SiG12D-LODER
Silexion's SiG12D-LODER represents a pioneering approach in the treatment of pancreatic cancer. This product is the culmination of extensive pre-clinical studies and has advanced into an open-label Phase I clinical trial. SiG12D-LODER is designed to deliver RNAi-based therapeutics specifically to pancreatic tumors, offering a new hope by targeting the genetic underpinnings of one of the most challenging cancers to treat.
-
Prostate-LODER
The Prostate-LODER project is expanding Silexion's cancer treatment portfolio into prostate cancer, one of the most common cancer types among men. Currently in pre-clinical studies, this innovative product aims to leverage the LODER platform to offer targeted and effective treatment options for patients battling prostate cancer, promising a new frontier in the fight against this prevalent disease.
-
GBM-LODER
Glioblastoma Multiform (GBM), a malignant primary brain tumor, represents one of the most aggressive and difficult-to-treat cancers. Silexion Therapeutics' GBM-LODER is in pre-clinical studies, aiming to target and treat GBM with unprecedented precision. By exploiting RNA interference mechanisms, GBM-LODER hopes to offer a breakthrough in the treatment of a condition where current treatment options are limited and prognosis is often poor.
